24 July 2014
A new type of treatment may offer hope to people suffering from metastatic brain cancer, which affects over half of patients who are diagnosed with a brain tumour, a study suggests.
Metastatic cancer has no treatment and detrimental outcomes in most cases, but a new study from the Cincinnati Cancer Center (CCC), published in the journal Oncotarget, claims that previously studied SapC-DOPS could be used for the treatment of brain cancer that has spread.
The research was led by Dr Xiaoyang Qi, member of the CCC, who said the SapC-DOPS - a combination of two natural cellular components - caused cell death in cancer cell types, including brain, lung, skin, prostate, blood, breast and pancreatic cancer, while sparing normal cells and tissue.
In the study, the team evaluated the ability of SapC-DOPS to selectively target brain metastases of human breast and lung cancer cells in cultures and in animal models, which proved successful.
Dr Qi commented: "These results support the potential of SapC-DOPS for the diagnosis and therapy of primary and metastatic brain tumors which is critically needed to increase survival rates of patients with this illness."
Posted by Philip Briggs
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.